Showing results (371-380 of 793) with videos related to
Sort By:
Pageof 80
Leukemia & Lymphoma|March 31, 2009
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myelomaLuciano J Costa, Shaji Kumar, Angela Dispenzieri, et al.European Journal of Haematology|February 9, 2017
Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysisMaria Mainou, Anastasia-Vasiliki Madenidou, Aris Liakos, et al.Journal for Immunotherapy of Cancer|January 11, 2021
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II studySuchita Pakkala, Kristin Higgins, Zhengjia Chen, et al.Blood Cancer Discovery|July 24, 2023
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene VicleucelBruno Paiva, Irene Manrique, Julie Rytlewski, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 4, 2015
New cancers after autotransplantations for multiple myelomaAnuj Mahindra, Girindra Raval, Paulette Mehta, et al.The Lancet. Oncology|December 3, 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaS Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, et al.Leukemia & Lymphoma|May 16, 2014
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphomaLoretta J Nastoupil, Pareen J Shenoy, Alex Ambinder, et al.Cancer|November 28, 2018
Safety and survival outcomes for bloodless transplantation in patients with myelomaNisha S Joseph, Jonathan L Kaufman, Lawrence H Boise, et al.The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.Blood Advances|January 4, 2018
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myelomaTineke Casneuf, Xu Steven Xu, Homer C Adams, et al.Pageof 80